Founders
Dr. Henrik Klitgaard
Scientific Co-Founder, Board Member
Previously, Henrik was VP for Neuroscience at UCB where his team identified the novel synaptic vesicle 2A mechanism for epilepsy and two antiepileptic drugs, Keppra and Briviact. Keppra was the first blockbuster drug for epilepsy. Henrik is former member of the Scientific Committee at Citizens United for Research in Epilepsy, and current member of the External Consultant Board at the Epilepsy Therapy Screening Project at National Institutes of Health (NIH) in US. He is recipient of the Accelerator Award from the US Epilepsy Foundation in recognition of his long-time commitment to the epilepsy community and advancement of important new therapies for epilepsy.
Scientific Co-Founder, CSO, Board Member
Sakari Kauppinen is Professor and Director of the Center for RNA Medicine, Dept of Clinical Medicine, Aalborg University. Prior to joining Aalborg University, Sakari was the Senior Director of miRNA Research & Drug Discovery at Santaris Pharma (acquired by Roche in 2014) where he supervised discovery of Miravirsen – the world’s first microRNA-targeted drug. He was a member of the clinical development team that successfully advanced Miravirsen to clinical phase 2 trials with on-target efficacy against HCV infection and a good safety profile. Sakari is also co-founder of Resalis Therapeutics, and received $9.2M in 2019 from Novo Nordisk Foundation for a NASH Research Consortium.
Prof. Sakari Kauppinen
Management
CEO
Lars Hellerung Christiansen
Co-Founder, BD, Board Member
Co-Founder, CFO and Board Member
Mads Rasmussen
